High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis
International Journal of Chronic Obstructive Pulmonary Disease · 2023-04 · Volume 18 · 469-482
DOI: 10.2147/copd.s401736 ↗At a glance
Metaanalyse in International Journal of Chronic Obstructive Pulmonary Disease, 2023-04. Written by Paraschos Archontakis Barakakis and 6 co-authors. Institution: Northeast Internal Medicine Associates, LaGrange, IN, USA. Major MEDLINE topics: Pulmonary Disease, Chronic Obstructive, Pneumonia. Cited 11 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC 3.0).
Abstract (original language)
Background
Inhaled corticosteroids (ICSs) combined with bronchodilators have been identified to improve outcomes in COPD but also to be associated with certain adverse effects.
Objective
We performed a systematic review and meta-analysis to compile and summarize data on the efficacy and safety of dosing levels (high versus medium/low) of ICS alongside ancillary bronchodilators following PRISMA guidelines. Data Sources: Medline and Embase were systematically searched until December 2021. Randomized, clinical trials (RCTs) that met predefined inclusion criteria were included. Data Extraction: Risk ratios (RRs) with 95% confidence intervals (CI) were extracted. Any acute exacerbation of COPD (AECOPD) risk was chosen as the primary efficacy outcome, mortality rate as the primary safety outcome, moderate/severe AECOPD risk as the secondary efficacy outcome and pneumonia risk as the secondary safety outcome. Subgroup analyses of individual ICS agents, of patients with baseline moderate/severe/very severe COPD and of patients with recent COPD exacerbation history were also performed. A random-effects model was used.
Results
We included 13 RCTs in our study. No data on low doses were included in the analysis. High dose ICS was not associated with a statistically significant difference in any AECOPD risk (RR: 0.98, 95% CI: 0.91-1.05, I2: 41.3%), mortality rate (RR: 0.99, 95% CI: 0.75-1.32, I2: 0.0%), moderate/severe AECOPD risk (RR: 1.01, 95% CI: 0.96-1.06, I2: 0.0%) or pneumonia risk (RR: 1.07, 95% CI: 0.86 -1.33, I2: 9.3%) compared to medium dose ICS. The same trend was identified with the several subgroup analyses.
Conclusion
Our study collected RCTs investigating the optimal dosing level of ICS prescribed alongside ancillary bronchodilators to patients with COPD. We identified that the high ICS dose neither reduces AECOPD risk and mortality rates nor increases pneumonia risk relative to the medium dose.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Northeast Internal Medicine Associates, LaGrange, IN, USA.
- Division of Pulmonary, Critical Care, and Occupational Medicine, Department of Internal Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA, USA.
- Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.
- Department of Medicine, Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, USA.
- Departments of Medicine and Genetic Medicine, Weill Cornell Medicine, New York, NY, USA.
- Veterans Rural Health Resource Center, VA Office of Rural Health, and Center for Access and Delivery Research and Evaluation (CADRE) at the Iowa City VA Healthcare System, Iowa City, IA, USA.
ORCID profiles: Paraschos Archontakis Barakakis, Fernando J Martinez
Cite
APA
Archontakis Barakakis, P., Tran, T., You, J. Y., Hernandez Romero, G. J., Gidwani, V., Martinez, F. J., & Fortis, S. (2023). High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis. International Journal of Chronic Obstructive Pulmonary Disease, Volume 18, 469-482. https://doi.org/10.2147/copd.s401736
Vancouver
Archontakis Barakakis P, Tran T, You JY, Hernandez Romero GJ, Gidwani V, Martinez FJ, et al. High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis. International Journal of Chronic Obstructive Pulmonary Disease. 2023;Volume 18:469-482. doi:10.2147/copd.s401736
BibTeX
@article{ArchontakisBarakakis2023,
author = {Archontakis Barakakis, Paraschos and Tran, Thuonghien and You, Jee Young and Hernandez Romero, Gabriel J and Gidwani, Vipul and Martinez, Fernando J and Fortis, Spyridon},
title = {High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2023},
volume = {Volume 18},
pages = {469--482},
doi = {10.2147/copd.s401736}
}
EUVIMED